Earnings ·
Reports $9.6M net loss for nine months ended Sept. 30, 2026
REVBRevelation Biosciences, Inc.
Revelation Biosciences reported a net loss of $9.6 million, or $29.37 per share, for the nine months ended September 30, 2026, compared to a $6.4 million loss in the prior year period. For the third quarter, the company posted a net loss of $3.3 million, or $5.92 per share, against $1.9 million in the same period last year. Cash and cash equivalents decreased to $9.1 million from $10.7 million at year-end 2025, primarily due to operating activities offset by proceeds from a January 2026 warrant inducement. Management stated that current funds are sufficient to support operations into the second quarter of 2027. The company also announced it has selected a contract research organization for an upcoming study evaluating its lead candidate, Gemini, in patients with acute kidney injury.